Eosinophilic Esophagitis | Treatment Algorithms: Claims Data Analysis | US | 2022

Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty in swallowing food and the potential for dangerous food impaction. The indication has no FDA-approved therapy. While generically available treatments, such as proton pump inhibitors (PPIs) and topical steroids, are the mainstays of clinical management of EoE, several therapies are in the pipeline (e.g., Dupixent [Sanofi / Regeneron], Fasenra [AstraZeneca]). As the EoE treatment landscape evolves, this report offers insight from real-world claims data into prescribing trends in EoE to help developers better understand current treatment and define the market niche for their emerging product.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed EoE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed EoE patients?
  • How have biologics been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of EoE patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis? What percentage of EoE patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.


Markets covered: United States

Key companies: Sanofi / Regeneron, AstraZeneca, GlaxoSmithKline, Pfizer, Novartis

Key drugs: PPIs (e.g., omeprazole, pantoprazole, esomeprazole), topical glucocorticoids (e.g., fluticasone propionate), oral / systemic glucocorticoids (e.g., prednisone), select biologics (e.g., dupilumab [Dupixent], benralizumab [Fasenra])


The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Login to access report